Bill Few Associates Inc. Lowers Holdings in Eli Lilly and Company $LLY

Bill Few Associates Inc. cut its holdings in Eli Lilly and Company (NYSE:LLY) by 5.9% during the second quarter, Holdings Channel reports. The firm owned 2,278 shares of the company’s stock after selling 143 shares during the quarter. Bill Few Associates Inc.’s holdings in Eli Lilly and Company were worth $1,776,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. Hazlett Burt & Watson Inc. lifted its holdings in Eli Lilly and Company by 20.7% in the 2nd quarter. Hazlett Burt & Watson Inc. now owns 1,840 shares of the company’s stock worth $1,434,000 after purchasing an additional 316 shares in the last quarter. Index Fund Advisors Inc. lifted its holdings in Eli Lilly and Company by 159.7% in the 2nd quarter. Index Fund Advisors Inc. now owns 1,218 shares of the company’s stock worth $950,000 after purchasing an additional 749 shares in the last quarter. M3 Advisory Group LLC raised its holdings in shares of Eli Lilly and Company by 5.0% during the 2nd quarter. M3 Advisory Group LLC now owns 636 shares of the company’s stock worth $496,000 after acquiring an additional 30 shares in the last quarter. Yarger Wealth Strategies LLC raised its holdings in shares of Eli Lilly and Company by 24.1% during the 2nd quarter. Yarger Wealth Strategies LLC now owns 577 shares of the company’s stock worth $450,000 after acquiring an additional 112 shares in the last quarter. Finally, Sharp Financial Services LLC raised its holdings in shares of Eli Lilly and Company by 13.1% during the 2nd quarter. Sharp Financial Services LLC now owns 431 shares of the company’s stock worth $336,000 after acquiring an additional 50 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LLY has been the topic of several recent research reports. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a report on Friday. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Finally, HSBC upped their price objective on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $948.06.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $833.08 on Monday. The company has a market cap of $788.47 billion, a P/E ratio of 54.45, a P/E/G ratio of 1.18 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The business’s 50 day moving average price is $742.42 and its 200-day moving average price is $765.55. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.